Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Genmab A/S banner

Genmab A/S
DUS:GE9

Watchlist Manager
Genmab A/S Logo
Genmab A/S
DUS:GE9
Watchlist
Price: 313.8 EUR 0.77% Market Closed
Market Cap: €20.5B
Write Note Create Alert Ask AI

Bankruptcy Probability

Genmab A/S's probability of bankruptcy is 1.1%, making a collapse highly unlikely. The solvency score is 51/100 — a warning sign of potential financial weakness.

We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.

Very Low
Probability of Bankruptcy

Financial Position

Cash & Short-Term Investments
+
3Y
-59%
5Y
-47%
10Y
+167%
Long-Term Investments
+
3Y
+34%
5Y
-70%
10Y
-
Debt
+
3Y
+4 594%
5Y
+8 002%
10Y
-

Solvency Ratios

Solvency Ratios Comparison
Genmab A/S Competitors

Country Company Market Cap D/E D/A Interest
Coverage 		Altman
Z-Score 		Quick
Ratio 		Current
Ratio 		Cash
Ratio
DK
Genmab A/S
CSE:GMAB
143.9B DKK
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
AbbVie Inc
NYSE:ABBV
462.2B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Amgen Inc
NASDAQ:AMGN
228B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Gilead Sciences, Inc
NASDAQ:GILD
185B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
132.5B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.4B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Moderna Inc
NASDAQ:MRNA
76.8B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
AU
CSL Ltd
ASX:CSL
85.4B AUD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
NL
argenx SE
XBRU:ARGX
52.6B EUR
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Natera Inc
NASDAQ:NTRA
59.4B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
US
Revolution Medicines Inc
NASDAQ:RVMD
44B USD
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
No Stocks Found

Continue GE9 Research

Summary
GE9 intrinsic value, competitors valuation, and company profile.
DCF Valuation
GE9 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GE9 stock valuation using valuation multiples.
Wall St Estimates
GE9 price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GE9 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Genmab A/S listings:
NASDAQ • USD
GMAB
 OTC • USD
GNMSF
 F • EUR
GE9
 F • EUR
GE91
 CSE • DKK
GMAB
 SWB • EUR
GE9
Discover More
Is Genmab A/S at risk of bankruptcy?

Genmab A/S's probability of bankruptcy is 1.1%, making a collapse highly unlikely.

The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.

How much debt does Genmab A/S have?

As of the latest report, Genmab A/S has total debt of 5B USD. This includes both short-term (0 USD) and long-term (5B USD) debt.

You can find a full breakdown on its Balance Sheet.

Back to Top
ALPHA SPREAD
Follow us
Join 359,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.